News

Filter

1 to 9 of 12 results

Takeda and BioMotiv in strategic partnership, including investment

Takeda and BioMotiv in strategic partnership, including investment

25-09-2014

Japan’s largest drugmaker Takeda Pharmaceutical has made a strategic investment in USA-based BioMotiv,…

BioMotivCardio-vascularFinancialImmunologicalsInflammatory diseasesJapanPharmaceuticalResearchTakeda PharmaceuticalUSA

AstraZeneca plans more job cuts; inks $240M-plus deal with Moderna; expands alliance with Karolinska Institutet

21-03-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN), ahead of its Investor Day briefing in New York later…

AstraZenecaCardio-vascularFinancialImmunologicalsInflammatory diseasesLicensingModerna TherapeuticsOncologyPharmaceuticalResearch

FDA calls for more data on Merck combo drug; Good results with allergy drug

06-03-2012

The US Food and Drug Administration (FDA) has issued a Complete Response Letter to drug giant Merck &…

ALK AbelloatorvastatinCardio-vascularezetimibeImmunologicalsMerck & CoNorth AmericaPharmaceuticalRegulationResearch

EMA says risk-benefit of ARBs positive; acts on Advagraf and Protelos/Osseor

21-10-2011

In a flurry of late news yesterday from the European Medicines Agency and its Committee for Medicinal…

AdvagrafAnti-Arthritics/RheumaticsAstellas PharmaCardio-vascularEuropeImmunologicalsPharmaceuticalProtelosRegulationServier

Johnson & Johnson highlights R&D pipeline with plans to file for 11 drug approvals by 2015; GAVI seat for Crucell

27-05-2011

US health care major Johnson & Johnson (NYSE: JNJ) yesterday reviewed its growth strategies for its Pharmaceuticals…

Antibiotics and Infectious diseasesCardio-vascularImmunologicalsJohnson & JohnsonOncologyPharmaceuticalResearchVaccines

Pfizer signs up to $511 million deal for Lpath’s AMD treatment and $134 million accord for Phylogica’s for peptide-based vaccines

21-12-2010

US drug behemoth Pfizer (NYSE: PFE) - which just a couple of weeks ago dumped its chief executive Jeff…

AsonepCardio-vascularImmunologicalsiSONEPLicensingLpathOncologyOpthalmicsPfizerPharmaceuticalPhylogica

Dutch firm Pharming initiates DNage divestment, to focus on Rhucin

18-05-2010

Netherlands-based biotechnology company Pharming Group NV said yesterday that it has initiated the process…

BiotechnologyCardio-vascularDNageFinancialImmunologicalsMergers & AcquisitionsPharmaceuticalPharmingResearchRhucin

1 to 9 of 12 results

Back to top